Daniel Spratt MD
Central Nervous System Cancer, Urologic Cancer
Physician
Join to view full profile
11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-1700
Fax+1 216-286-3989
Dr. Spratt is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Daniel Spratt is a radiation oncologist in Cleveland, OH and is affiliated with UH Cleveland Medical Center. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 10 years. He specializes in urologic cancer and is experienced in prostate cancer.
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2011 - 2015
Spartanburg Medical CenterInternship, Transitional Year, 2010 - 2011
Vanderbilt University School of MedicineClass of 2010
Certifications & Licensure
OH State Medical License 2021 - 2027
MI State Medical License 2015 - 2022
NY State Medical License 2011 - 2016
SC State Medical License 2010 - 2011
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsCharacterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically locali...Udit Singhal, Ralph Jiang, James A Proudfoot, Elizabeth Chase, Krithika Suresh
Prostate Cancer and Prostatic Diseases. 2026-09-01 - IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.Dimitrios Doultsinos, Ingrid Tomljanovic, Eleftherios Pilalis, Sophia M Abusamra, Mohammed Alshalalfa
EMBO Molecular Medicine. 2026-08-22 - Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.Rodney J Ellis, Stephanie L Pugh, James B Yu, Felix Y Feng, Andre A Konski
JAMA. 2026-08-13
Press Mentions
AI Prostate Tool Analyses Biopsy Images to Predict Metastasis & Mortality RisksDecember 3rd, 2025- Age Should Matter More in Prostate Cancer Treatment, Study FindsNovember 12th, 2025
- Researchers at University Hospitals Seidman Cancer Center Highlight Age as Key Factor in Metastatic Prostate Cancer Treatment StrategiesNovember 10th, 2025
Grant Support
- Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteCASE WESTERN RESERVE UNIVERSITY2019–2032
- Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate CancerCASE WESTERN RESERVE UNIVERSITY2021–2028
- Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate CancerCASE WESTERN RESERVE UNIVERSITY2021–2028
- Individualized estimates of treatment benefit from hormone therapy for men with prostate cancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2025
- Individualized estimates of treatment benefit from hormone therapy for men with prostate cancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
